Table 2. Univariable Linear Regression Analysis for Accumulated Milligram Morphine Equivalents During Days 0 to 5 After Major Colorectal Surgery in 842 Patients.
| Factor | Coefficient (SE) | t Ratio | P value |
|---|---|---|---|
| Minimally invasive surgery (yes vs no) | 6.01 (3.9) | 1.54 | .12 |
| Individualized opioid regimen (yes vs no) | −24.29 (3.49) | −6.96 | <.001 |
| Gabapentin (yes vs no) | −38.06 (4) | −9.51 | <.001 |
| Clonidine (yes vs no) | 15.08 (3.84) | 3.92 | <.001 |
| Sex (female vs male) | 4.74 (3.53) | 1.34 | .18 |
| Age, y | −0.92 (0.11) | −8.41 | <.001 |
| BMI | −0.30 (0.39) | −0.76 | .45 |
| ASA group (I-II vs III-IV) | 4.65 (4.2) | 1.11 | .27 |
| Smoker (yes vs no) | 17.25 (7.72) | 2.24 | .03 |
| Diagnosis (IBD vs other) | 29.71 (4.74) | 6.27 | <.001 |
| Magnitude of surgery (abdomino-pelvic vs abdominal) | −5.81 (3.88) | −1.5 | .14 |
| Regional analgesia (spinal vs epidural) | −10.36 (3.87) | −2.67 | .008 |
| Compliance to ERAS protocol components (%) | −0.72 (0.14) | −5.10 | <.001 |
| Complications (yes vs no) | −4.99 (4.58) | −1.09 | .28 |
Abbreviations: ASA, American Society of Anesthesiologists; BMI, body mass index (calculated as weight in kilograms divided by height in meters squared); ERAS, enhanced recovery after surgery; IBD, inflammatory bowel disease.